Trial Profile
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 04 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 04 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2020 Planned number of patients changed from 133 to 147.